Chronic cerebrovascular diseases and neuroprotection: the clinical efficacy of meldonium (Mildronat)

Tanashyan, M. M.; Maksimova, M. Yu.; Шабалина, А.А.; Федин, П.А.; Медведев, Р.Б.; Bolotova, T.A.

doi:10.17116/jnevro202012010114

Cited by 8 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical studies have suggested that meldonium may exert neuroprotective effects by modulating cellular energy metabolism, reducing oxidative stress, and inhibiting apoptosis in neuronal cells. These neuroprotective mechanisms could potentially contribute to cognitive enhancement or delay neurodegeneration, but clinical evidence in humans is still lacking [29]. Research by Cristo et al ( 2018) highlights meldonium's ability to improve mitochondrial dysfunction in Huntington's disease by restoring the expression of peroxisome proliferator-activated receptor γ coactivator 1α [21].…”

Section: Neuroprotective Effects and Other Indicationsmentioning

confidence: 99%

“…Over the duration of Mildronate treatment, patients demonstrated a notable reduction in levels of reactive anxiety, which refers to the temporary state of heightened anxiety or tension stemming from a particular situation or stressor [29]. Additionally, there was an observed decline in personality-related or trait anxiety, which is the predisposition to perceive many situations as threatening and to experience anxiety more frequently and intensely than others [29]. The amelioration of anxiety symptoms, in conjunction with improvements in depressive symptoms previously reported, point to Mildronate's broader psychotropic capabilities beyond its primary cardiovascular indications.…”

Section: Psychiatric Benefits and Potential Treatment For Mental Heal...mentioning

confidence: 99%

See 1 more Smart Citation

Unlocking the Potential of Meldonium: From Performance Enhancement to Therapeutic Insights

Bellman

2024

Psychoactives

View full text Add to dashboard Cite

Meldonium, a promising pharmacological agent initially developed for cardiovascular indications, has sparked considerable interest in recent years due to its potential performance-enhancing effects. This review manuscript delves into the multifaceted roles of meldonium, examining its pharmacological mechanisms, therapeutic applications, and controversial implications in medicine. Beyond its cardiovascular applications, emerging research has shed light on meldonium’s neuroprotective properties and its potential for mitigating various psychiatric conditions. Moreover, recent investigations have explored meldonium’s potential in treating neurodegenerative disorders, alcohol use disorder, and even enhancing cognitive function. However, meldonium’s journey extends beyond the realm of medicine, as its use among athletes has stirred debates surrounding performance enhancement and fair competition. The substance’s inclusion in the World Anti-Doping Agency’s (WADA) prohibited list has intensified scrutiny and raised ethical considerations regarding its use in sports. This manuscript aims to provide a comprehensive resource for researchers, clinicians, and enthusiasts alike, fostering a deeper understanding of meldonium’s complex biological interactions and its potential contributions to psychiatry.

show abstract

Section: Neuroprotective Effects and Other Indicationsmentioning

confidence: 99%

Section: Psychiatric Benefits and Potential Treatment For Mental Heal...mentioning

confidence: 99%

Unlocking the Potential of Meldonium: From Performance Enhancement to Therapeutic Insights

Bellman

2024

Psychoactives

View full text Add to dashboard Cite

show abstract

New treatment options for a patient with chronic heart failure and chronic obstructive pulmonary disease

et al. 2022

View full text Add to dashboard Cite

Introduction. The number of patients with chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD) is increasing every year. In both CHF and COPD, secondary mitochondrial dysfunction is observed. In this regard, the attention of researchers is attracted by drugs that have their therapeutic effects at the level of mitochondria, one of which is meldonium. Meldonium has proven itself in the treatment of various diseases, however, the evaluation of the clinical efficacy of meldonium has not yet been carried out in comorbid patients with CHF and COPD.Aim. To study the effects of meldonium as part of basic therapy on the clinical condition, the main functional parameters of the heart and lungs, and the quality of life in patients with CHF and COPD.Materials and methods. The randomized open study included 60 patients with CHF II A stage, II–III FC (clinical recommendations of the RSC, OSSN 2020) and COPD I–III degree of airflow limitation (GOLD 2021 classification) in remission (age 45–70 years). The patients were divided into 2 groups: the 1st group – the main group (n = 30) with CHF and COPD took meldonium at a dosage of 1000 mg/day in addition to the basic therapy, the 2nd group – the control group (n = 30) was only on basic therapy for CHF and COPD. The observation period is 12 weeks.Results. In patients with CHF and COPD, in the dynamics of therapy with the inclusion of meldonium, as a result, the severity of clinical symptoms decreased, improvement was revealed in the main structural and functional parameters of the heart, external respiration function, and quality of life.Conclusions: a significant beneficial effect of combination therapy with the inclusion of meldonium on the clinical and functional parameters of the heart and lungs, indicators of quality of life in patients with CHF and COPD has been established, which makes it possible to recommend the use of meldonium as part of combination therapy in comorbid patients.

show abstract

New opportunities for neuroprotective therapy of patients in the acute and early recovery period of ischemic stroke

Tanashyan

Raskurazhev²,

Zaslavskaya³

et al. 2022

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To evaluate the efficacy and safety of Brainmax in comparison with ethylmethylhydroxypyridine succinate and trimethylhydrazinium propionate in patients with ischemic stroke in the acute and early recovery period. Materials and methods. An open multicenter randomized study included 180 patients aged 1880 years (mean age 60.917.66 years, men 47.8%) with ischemic stroke in the acute and early recovery period (NIHSS from 3 to 15 points). Patients were randomized to receive Brainmax, ethylmethylhydroxypyridine succinate and trimethylhydrazinium propionate in an equal ratio (n=60). The drugs were administered intravenously for 10 days, followed by a transition to intramuscular injection for 14 days. Efficacy was assessed using the following scales: Modified Rankin Scale, NIHSS, Rivermead Mobility Index, Montreal Cognitive Assessment Scale (MoCA). Safety assessment was carried out according to the presence and structure of adverse events. Results. The mean Modified Rankin Scale score for Visits 3 (day 10) and 5 (day 25) for the group treated with Brainmax was 2.410.85 and 1.440.91 points, for the group EMHPS 2.870.68 and 2.180.85 points, and for the group receiving trimethylhydrazinium propionate 2.870.50 and 2.550.70 points respectively, which reflects the best functional outcome in the Brainmax group (p0.05). Comparison of cognitive function indicators also showed statistically significant differences between the groups of drugs Brainmax and ethylmethylhydroxypyridine succinate. Evaluation according to the MoCA test showed that the use of Brainmax is 20% more effective in restoring cognitive functions (compared to monodrugs). Conclusion. The present study confirms the superiority of combination therapy with Brainmax over monotherapy with each of the components.

show abstract

Chronic cerebrovascular diseases and neuroprotection: the clinical efficacy of meldonium (Mildronat)

Cited by 8 publications

References 19 publications

Unlocking the Potential of Meldonium: From Performance Enhancement to Therapeutic Insights

Unlocking the Potential of Meldonium: From Performance Enhancement to Therapeutic Insights

New treatment options for a patient with chronic heart failure and chronic obstructive pulmonary disease

New opportunities for neuroprotective therapy of patients in the acute and early recovery period of ischemic stroke

Contact Info

Product

Resources

About